Vessel size and outcome after coronary drug-eluting stent placement: results from a large cohort of patients treated with sirolimus- or paclitaxel-eluting stents
- PMID: 17010786
- DOI: 10.1016/j.jacc.2006.05.068
Vessel size and outcome after coronary drug-eluting stent placement: results from a large cohort of patients treated with sirolimus- or paclitaxel-eluting stents
Abstract
Objectives: This study sought to investigate the influence of vessel size on the outcomes of patients after drug-eluting stent (DES) implantation.
Background: There are no dedicated studies on the influence of vessel size on the outcomes of patients treated with different DES.
Methods: The study population was composed of 2,058 consecutive patients who received sirolimus-eluting stents (SES) or paclitaxel-eluting stents (PES). Patients were grouped into tertiles according to vessel size (<2.41 mm in the lower tertile, 2.41 to 2.84 mm in the middle tertile, and >2.84 mm in the upper tertile). The primary end point was target lesion revascularization (TLR). Secondary end points were binary angiographic restenosis and the composite of death or myocardial infarction.
Results: Vessel size did not influence the composite end point of death and myocardial infarction. The TLR rates were higher among patients in the lower tertile (12.1%) as compared with the middle (8.4%) and upper (8.0%) tertiles (p = 0.02). In a multivariate analysis, vessel size emerged an independent predictor of TLR (p = 0.009). The model showed also a significant interaction between DES type and vessel size regarding TLR (p = 0.008). There was a significant difference in TLR rates among patients treated with SESs (8.6%) and PESs (16.4%) in the lower tertile (p = 0.002), but not in the middle and upper tertiles.
Conclusions: The influence of vessel size on restenosis is related to the specific DES used, with SESs providing better outcomes than PESs in small but not in large coronary vessels.
Comment in
-
All drug-eluting stents are equal, but some drug-eluting stents are more equal than others.J Am Coll Cardiol. 2006 Oct 3;48(7):1310-1. doi: 10.1016/j.jacc.2006.07.013. Epub 2006 Sep 12. J Am Coll Cardiol. 2006. PMID: 17010787 No abstract available.
Similar articles
-
Drug-eluting stent for the treatment of small coronary lesion: comparison between sirolimus- and paclitaxel-eluting stent.Chin Med J (Engl). 2007 Apr 5;120(7):569-73. Chin Med J (Engl). 2007. PMID: 17442204
-
Comparison of sirolimus-eluting stent, paclitaxel-eluting stent, and bare metal stent in the treatment of long coronary lesions.Catheter Cardiovasc Interv. 2006 Feb;67(2):181-7. doi: 10.1002/ccd.20586. Catheter Cardiovasc Interv. 2006. PMID: 16400663
-
Outcomes after unrestricted use of everolimus-eluting stent compared to paclitaxel- and sirolimus-eluting stents.Am J Cardiol. 2011 Jun 15;107(12):1757-62. doi: 10.1016/j.amjcard.2011.02.330. Epub 2011 Apr 15. Am J Cardiol. 2011. PMID: 21497782
-
A meta-analysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease.J Am Coll Cardiol. 2007 Oct 2;50(14):1373-80. doi: 10.1016/j.jacc.2007.06.047. Epub 2007 Aug 21. J Am Coll Cardiol. 2007. PMID: 17903638 Review.
-
Robustness of late lumen loss in discriminating drug-eluting stents across variable observational and randomized trials.Circulation. 2005 Nov 1;112(18):2833-9. doi: 10.1161/CIRCULATIONAHA105.570093. Circulation. 2005. PMID: 16267256 Review.
Cited by
-
Risk prediction model for in-stent restenosis following PCI: a systematic review.Front Cardiovasc Med. 2024 Aug 29;11:1445076. doi: 10.3389/fcvm.2024.1445076. eCollection 2024. Front Cardiovasc Med. 2024. PMID: 39267809 Free PMC article.
-
Clinical Outcome after Everolimus-Eluting Stent Implantation for Small Vessel Coronary Artery Disease: XIENCE Asia Small Vessel Study.Chonnam Med J. 2024 Jan;60(1):78-86. doi: 10.4068/cmj.2024.60.1.78. Epub 2024 Jan 25. Chonnam Med J. 2024. PMID: 38304131 Free PMC article.
-
Coronary In-Stent Restenosis: Predictors and Treatment.Dtsch Arztebl Int. 2021 Sep 24;118(38):637-644. doi: 10.3238/arztebl.m2021.0254. Dtsch Arztebl Int. 2021. PMID: 34379053 Free PMC article. Review.
-
Outcomes of patients treated with a biodegradable-polymer sirolimus-eluting stent versus durable-polymer everolimus-eluting stents after rotational atherectomy.Clin Res Cardiol. 2021 Oct;110(10):1574-1585. doi: 10.1007/s00392-021-01852-9. Epub 2021 Apr 16. Clin Res Cardiol. 2021. PMID: 33861369
-
Ultrathin (60 μm), ultralong (≥40 mm) sirolimus-eluting stent: study of clinical and safety profiles among real-world patients.Anatol J Cardiol. 2021 Feb;25(2):111-119. doi: 10.14744/AnatolJCardiol.2020.40909. Anatol J Cardiol. 2021. PMID: 33583818 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
